Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

计划入组 75 人 · 首次发布于 2020 年 5 月 12 日

Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)

首次发布于 2021 年 11 月 4 日

Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab

计划入组 1 人 · 首次发布于 2021 年 3 月 10 日

Tetanus Toxin-ACVA Fusion Vaccine

solid tumors therapy

CLK3 inhibitor (oral, solid tumors), Biosplice Therapeutics

FUSION PHARMACEUTICALS

Nepal

Biomea Fusion

United States

Fusion Pharmaceuticals Inc.

Zenocutuzumab Achieves 30% Response Rate in NRG1 Fusion-Positive Solid Tumors, Receives FDA Approval

Merus' Bizengri Receives FDA Approval for NRG1 Fusion-Positive Cancers

FDA Extends Review of Zenocutuzumab for NRG1 Fusion-Positive Cancers